Difficulty: Medium
Average Score: 70%
Practice
A 79-year-old woman with a 1.5-cm breast cancer underwent lumpectomy. Pathology revealed ductal carcinoma that is hormone receptor negative (estrogen receptor 0%, progesterone receptor 1%) and HER2/neu negative. Surgical margins were adequate and uninvolved with cancer. Sentinel lymph node sampling was negative for lymph node involvement. She has good performance status and no activities of daily living (ADL) or instrumental (IADL) dependencies. What treatment would you recommend?
Correct answer
E
Rationale
The most appropriate treatment for this 79-year-old woman with hormone receptor-negative, HER2/neu-negative breast cancer, who underwent lumpectomy with clear margins and negative lymph nodes, would be observation or active surveillance, also known as watchful waiting. This approach is based on the fact that she has a good performance status, no ADL or IADL dependencies, and a low risk of cancer recurrence based on the favorable characteristics of her tumor.
Adjuvant chemotherapy (Option A) is not recommended in this case because the patient's tumor is hormone receptor-negative and HER2/neu-negative, making chemotherapy less effective as these types of tumors are less likely to respond to chemotherapy.
Adjuvant chemotherapy with radiation (Option B) is also not necessary as the patient has a low-risk tumor with clear margins and negative lymph nodes, making adjuvant radiation unnecessary.
Adjuvant radiation only (Option C) is not indicated as the patient's tumor characteristics do not warrant radiation therapy following lumpectomy.
Hormonal therapy only (Option D) is not the best choice because the patient's tumor is hormone receptor-negative, meaning hormonal therapy would not be effective in this case.
Educationally, this case highlights the importance of tailoring treatment based on individual patient characteristics and tumor biology. It is crucial to consider factors such as age, performance status, tumor characteristics, and risk of recurrence when making treatment decisions in breast cancer patients. Watchful waiting in low-risk patients can help avoid unnecessary treatments and their associated side effects, leading to better quality of life for the patient.
Adjuvant chemotherapy (Option A) is not recommended in this case because the patient's tumor is hormone receptor-negative and HER2/neu-negative, making chemotherapy less effective as these types of tumors are less likely to respond to chemotherapy.
Adjuvant chemotherapy with radiation (Option B) is also not necessary as the patient has a low-risk tumor with clear margins and negative lymph nodes, making adjuvant radiation unnecessary.
Adjuvant radiation only (Option C) is not indicated as the patient's tumor characteristics do not warrant radiation therapy following lumpectomy.
Hormonal therapy only (Option D) is not the best choice because the patient's tumor is hormone receptor-negative, meaning hormonal therapy would not be effective in this case.
Educationally, this case highlights the importance of tailoring treatment based on individual patient characteristics and tumor biology. It is crucial to consider factors such as age, performance status, tumor characteristics, and risk of recurrence when making treatment decisions in breast cancer patients. Watchful waiting in low-risk patients can help avoid unnecessary treatments and their associated side effects, leading to better quality of life for the patient.